Ozempic® (once-weekly injectable semaglutide) was associated with a 23% reduced risk of heart attack, stroke and death in people with type 2 diabetes and cardiovascular disease on Medicare versus dulaglutide1Data also highlighted Ozempic® was associated with a 26% lower risk of death versus dulaglutide1This study is the first to directly compare these glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications in everyday real-life use. It fills a significant gap in understanding their effects on heart ...

Production is under way and the pill, which helped patients lose an average 16.6% of their weight, is pending regulatory approval in the U.S. ...

PresentationOperator Okay. We are good to go. Welcome to this Novo Nordisk fireside at the 61st Edition of EASD here in Vienna. Welcome to all of you in the room and also welcome to those listening in online. Today's call will focus on the R&D and in the pipeline, and we're here today with Martin, who will take us through some of the developments later. Before we get into it, just a usual word of caution in terms of the forward-looking statements and that the future is unpredictable, that pertains, in parti ...

Core Viewpoint - Novo Nordisk's late-stage trial results for its oral obesity pill demonstrate significant weight reduction and tolerability, comparable to its existing Wegovy injection, highlighting the company's advancement in obesity treatment options [1][2]. Group 1: Trial Results - The phase 3 Oasis 4 trial indicated that the oral semaglutide pill resulted in an average weight reduction of 16.6% after 64 weeks in patients with obesity or overweight and at least one weight-related comorbidity [2]. - The oral treatment, referred to as the "Wegovy pill," provides an important alternative to the existing once-weekly injection, according to Novo Nordisk's Chief Science Officer [2][3]. Group 2: Efficacy and Safety - The company successfully demonstrated that the oral tablet can achieve the same efficacy, safety, and tolerability as the injectable version, allowing patients to choose between the two forms of treatment [3]. - The oral treatment utilizes the same Semaglutide GLP-1 medication that is the foundation of Novo Nordisk's current obesity and diabetes treatments, Wegovy and Ozempic [4]. Group 3: Regulatory Status and Production - The oral pill is currently under review by the U.S. Food and Drug Administration, with a decision expected in the fourth quarter of this year following its New Drug Application submission in February [5]. - If approved, the production of the pill will be fully based in the U.S., aligning with the trend of global pharmaceutical firms increasing their investments in U.S. manufacturing [5].

Core Insights - SoftBank's joint venture with OpenAI to provide AI services to corporate clients in Japan is significantly delayed [1] Group 1 - The joint venture aims to deliver artificial intelligence solutions to businesses in Japan [1] - The project is reportedly behind schedule, indicating potential challenges in execution [1]

礼来与诺和诺德的较量继续上演，此次战火蔓延到了口服药领域。 2025年9月17日，礼来公司公布了ACHIEVE-3研究的积极顶线结果。这项三期临床试验显示，礼来的在 研口服小分子GLP-1药物orforglipron在血糖控制和体重减轻方面均优于诺和诺德的口服司美格鲁肽。 这是口服GLP-1领域的首次头对头研究，1698名2型糖尿病患者的临床试验数据表明，orforglipron所有 剂量组均达到了主要终点和所有关键次要终点。在最高剂量下，orforglipron组患者糖化血红蛋白 （A1C）降幅达到2.2%，而口服司美格鲁肽最高剂量组仅为1.4%。 有券商医药行业分析师对21世纪经济报道记者指出，这一结果标志着小分子GLP-1药物首次在疗效上正 面突破多肽制剂的壁垒。 "此前市场担忧口服小分子因生物利用度问题难以匹敌注射或高剂量口服多肽，但Orforglipron通过中枢 神经渗透性优化和长效受体结合设计，验证了差异化路径的可行性。"该分析师说。 一场"头对头"对决 "值得注意的是，Orforglipron的36mg剂量组在疗效上或显著优于司美格鲁肽14mg，而安全性数据若与 既往一致，将直接挑战司美格鲁肽 ...

"减重药行业'卷'得有些过头了，都已经打到管线上了。"一位业内人士对第一财经记者表示。他指的是 对于尚未上市的GLP-1口服减重药，礼来和诺和诺德已经展开激烈竞争。 在美国市场，礼来已经开始疯狂抢占减重药的份额。凭借已经获批上市的GLP-1药物替尔泊肽，礼来的 市场占有率迅速增长，处方量甚至超越了司美格鲁肽。今年上半年，替尔泊肽减重和降糖两大适应症实 现了147亿美元的销售额。而诺和诺德已上市的三款司美格鲁肽药物累计销售额接近167亿美元。未来随 着司美格鲁肽药物口服减重药以及礼来的orforglipron陆续上市，两家减重药巨头的竞争将在全球范围升 级。 上个月，礼来国际业务总裁帕特里克·琼森（Patrik Jonsson）现身在上海举办的一场面向公众的活动， 宣传该公司的战略。在最新接受采访时，琼森表示，期望将礼来在美国市场的主导优势复制到全球。 一位跨国制药公司前高管对第一财经记者表示，礼来正在将美国市场的"消费者导向型"商业战略应用于 全球药品的布局，这意味着未来将加强与远程医疗及数字平台合作，满足更多自费患者的购药需求，而 不仅仅依赖于医保支付。 琼森也表示，礼来已经从美国市场学到"以消费者为核心" ...

Injectable GLP1s have transformed millions of people's weight loss journeys. But the race to bring needlefree options to market now heating up as ompic maker Novo Nordisk demonstrated in a new study that its pill form can achieve similar efficacy finding over 64 weeks clinical trial participants lost 13.6% of their body weight and an estimated 16.6% if continued. Having this available with the same efficacy, the same safety that gives patients a choice and that will expand the number of patients that we can ...

【原油】纽约商品交易所10月交货的轻质原油期货价格下跌47美分，收于每桶64.05美元，跌幅为 0.73%；11月交货的伦敦布伦特原油期货价格下跌52美分，收于每桶67.95美元，跌幅为0.76%。 智通财经APP获悉，周三，三大指数多数收跌。美联储宣布降息25个基点，这一举措得到了大多数特朗 普任命的美联储官员的支持，只有新任理事米兰反对，希望降息50个基点。在新闻发布会上，美联储主 席鲍威尔表示，今日的降息举措是一项风险管理决策，并补充说他认为没有必要快速调整利率。 【美股】截至收盘，道指涨260.42点，涨幅为0.57%，报46018.32点；纳指跌72.63点，跌幅为0.33%，报 22261.33点；标普500指数跌6.41点，跌幅为0.10%，报6600.35点。部分芯片股走低，博通(AVGO.US)跌 3.8%，英伟达(NVDA.US)跌2.6%、英特尔(INTC.US)跌1.4%。 纳斯达克中国金龙指数收涨2.85%，百度 (BIDU.US)收涨超11%，阿里巴巴(BABA.US)涨超2%。 【欧股】德国DAX30指数涨38.76点，涨幅0.17%，报23363.23点；英国富时100指数涨1 ...

welcome in our guest Jared Holes is on set healthcare strategist. Jared um first your reaction to Novo Eli and anything else you want and also it's kind of a little bit in left field but do we know a lot of people we tal I talked to on this on these drugs complain about muscle loss not fat loss and then they regain the weight. What do we know about these medications as of now.Well, great to be here. I think first of all, both trials seem to be pretty good. Like when you when you look at them for what they a ...